---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002147"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-04-10T23:59:59+00:00"
generated_at: "2026-05-23T17:49:00.819898+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioCryst CFO Anthony Doyle resigns; CEO Stonehouse takes interim CFO role

## Summary
- CFO Anthony Doyle resigns effective April 9, 2025; will provide transition consulting at $450/hour until May 31.
- CEO Jon P. Stonehouse appointed Interim CFO and Interim Principal Accounting Officer effective April 9.
- Company hired former public biotech CFO as financial consultant to support Stonehouse during CFO search.
- No change to Stonehouse's compensation arrangements resulting from the interim appointment.

## SEC filing metadata
- accession: 0001171843-25-002147
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-04-10T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325002147/0001171843-25-002147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325002147/f8k_040625.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002147
- JSON: https://secwatch.observer/filing/0001171843-25-002147.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002147.txt

## Key facts
- Executive change
  Anthony Doyle resigned as Chief Financial Officer and Interim Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.
  - Action: resigned
  - Role: Chief Financial Officer and Interim Principal Accounting Officer
  source text: Anthony Doyle, the Chief Financial Officer and Interim Principal Accounting Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184325002147/0001171843-25-002147-index.htm
- Executive change
  Jon P. Stonehouse was appointed as Interim Chief Financial Officer and Interim Principal Accounting Officer at BIOCRYST PHARMACEUTICALS INC.
  - Action: appointed
  - Role: Interim Chief Financial Officer and Interim Principal Accounting Officer
  source text: appointed Jon P. Stonehouse, the Company’s Chief Executive Officer, to serve as Interim Chief Financial Officer and Interim Principal Accounting Officer, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184325002147/0001171843-25-002147-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.